不同卵巢反应人群采用拮抗剂方案中不同扳机方式控制卵巢过度刺激(COH)的随机对照临床试验方案

注册号:

Registration number:

ChiCTR2200061825 

最近更新日期:

Date of Last Refreshed on:

2024-08-05 00:01:25 

注册时间:

Date of Registration:

2022-07-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同卵巢反应人群采用拮抗剂方案中不同扳机方式控制卵巢过度刺激(COH)的随机对照临床试验方案

Public title:

Randomized controlled clinical trial protocol to control ovarian hyperstimulation (COH) by different trigger methods in different ovarian response populations

注册题目简写:

不同卵巢反应人群的扳机方案

English Acronym:

Different trigger methods in different ovarian response populations

研究课题的正式科学名称:

不同卵巢反应人群采用拮抗剂方案中不同扳机方式控制卵巢过度刺激(COH)的随机对照临床试验方案

Scientific title:

Randomized controlled clinical trial protocol to control ovarian hyperstimulation (COH) by different trigger methods in different ovarian response populations

研究课题代号(代码):

Study subject ID:

2022XNIVFJKJRCT01

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

钱月 

研究负责人:

万琪/胡瑜凌 

Applicant:

Yue Qian 

Study leader:

Qi Wan/Hu Yuling 

申请注册联系人电话:

Applicant telephone:

+86 17671674331

研究负责人电话:

Study leader's
telephone:

+86 18280266982

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1471142745@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wanqi123@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区医学院路1号

研究负责人通讯地址:

四川省成都市锦江区毕昇路66号

Applicant address:

1 Yixueyuan Road, Yuzhong District, Chongqing

Study leader's address:

66 Bisheng Road, Jinjiang District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学

Applicant's institution:

Chongqing Medical University

研究负责人所在单位:

成都西囡妇科医院

Affiliation of the Leader:

Chengdu Xi'nan Gynecology Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2022)生殖伦理委员会伦审第(08)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

成都西囡妇科医院生殖伦理委员会

Name of the ethic committee:

Reproductive Ethics Committee of Chengdu Xi'nan Gynecology Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-05-27 00:00:00

伦理委员会联系人:

施伟

Contact Name of the ethic committee:

Wei Shi

伦理委员会联系地址:

四川省成都市锦江区毕昇路66号

Contact Address of the ethic committee:

66 Bisheng Road, Jinjiang District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

成都西囡妇科医院

Primary sponsor:

Chengdu Xi'nan Gynecology Hospital

研究实施负责(组长)单位地址:

四川省成都市锦江区毕昇路66号

Primary sponsor's address:

No. 66, Bisheng Road, Jinjiang District, Chengdu City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都西囡妇科医院

具体地址:

四川省成都市锦江区毕昇路66号

Institution
hospital:

Chengdu Xi'nan Gynecology Hospital

Address:

66 Bisheng Road, Jinjiang District, Chengdu, Sichuan

经费或物资来源:

Source(s) of funding:

none

研究疾病:

不孕症  

Target disease:

infertility

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

进行高质量的随机对照临床试验,来探讨不同卵巢反应人群(低反应、正常反应和高反应)不同扳机方式(单板机(hCG)、双扳机(hCG+GnRH-a))对妊娠结果的影响。  

Objectives of Study:

A high-quality randomized controlled clinical trial was conducted to explore the effects of different ovarian response groups (low response, normal response and high response) and different trigger methods (single board computer (hCG) and double trigger (hCG+GnRH-a)) on pregnancy results.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.患有输卵管积水的女性,以及患有糖尿病、高血压、先天性肾上腺增生、库欣综合征、先天性子宫异常疾病、反复植入失败(≥2次移植)等内分泌疾病的女性;
2.严重不受控制的医学或代谢紊乱的夫妇也被排除在外;
3.补ICSI的患者。

Exclusion criteria:

1. Women with hydrosalpingers, and women with endocrine diseases such as diabetes, hypertension, congenital adrenal hyperplasia, Cushing's syndrome, congenital uterine abnormalities, and repeated implant failure (two transplants);
2. Couples with severe uncontrolled medical or metabolic disorders were also excluded.
3. Patient with an ICSI (intracytoplasmic sperm injection) cycle.

研究实施时间:

Study execute time:

From 2023-03-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-27 00:00:00 To 2024-04-30 00:00:00

干预措施:

Interventions:

组别:

卵巢低反应人群

样本量:

155

Group:

Patients with low ovarian response

Sample size:

干预措施:

HCG2000IU+GnRH-a0.2mg

干预措施代码:

Intervention:

HCG 2000 IU+GnRH-a 0.2 mg

Intervention code:

组别:

卵巢低反应人群

样本量:

155

Group:

Patients with low ovarian response

Sample size:

干预措施:

HCG6000IU+GnRH-a0.2mg

干预措施代码:

Intervention:

HCG 6000 IU+GnRH-a 0.2 mg

Intervention code:

组别:

卵巢正常反应人群

样本量:

65

Group:

Patients with normal ovarian response

Sample size:

干预措施:

hCG1000IU+GnRH-a0.2mg

干预措施代码:

Intervention:

hCG 1000 IU+GnRH-a 0.2 mg

Intervention code:

组别:

卵巢正常反应人群

样本量:

65

Group:

Patients with normal ovarian response

Sample size:

干预措施:

hCG6000IU(丽得宝)+GnRH-a0.1mg

干预措施代码:

Intervention:

hCG6000IU (Lidepot)+GnRH-a 0.1 mg

Intervention code:

组别:

卵巢高反应人群

样本量:

134

Group:

Patients with high ovarian response

Sample size:

干预措施:

GnRH-a0.2mg

干预措施代码:

Intervention:

GnRH-a 0.2 mg

Intervention code:

组别:

卵巢高反应人群

样本量:

134

Group:

Patients with high ovarian response

Sample size:

干预措施:

hCG1000IU+GnRH-a0.2mg

干预措施代码:

Intervention:

hCG 1000 IU+GnRH-a 0.2 mg

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都西囡妇科医院 

单位级别:

二级 

Institution
hospital:

Chengdu Xinan Gynecology Hospital

Level of the institution:

Secondary

测量指标:

Outcomes:

指标中文名:

临床妊娠率

指标类型:

主要指标

Outcome:

Clinical pregnancy rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

优胚率

指标类型:

主要指标

Outcome:

Excellent embryo rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MII卵率

指标类型:

主要指标

Outcome:

MII oocyte rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

继续妊娠率

指标类型:

主要指标

Outcome:

Continuing pregnancy rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

早期流产率

指标类型:

主要指标

Outcome:

Early abortion rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

活产率

指标类型:

主要指标

Outcome:

live birth rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

获卵数

指标类型:

次要指标

Outcome:

Number of oocytes obtained

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

重度OHSS发生率

指标类型:

次要指标

Outcome:

Incidence of severe ovarian hyperstimulation syndrome (OHSS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

取消周期率

指标类型:

次要指标

Outcome:

Cancel the cycle rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无胚可用率

指标类型:

次要指标

Outcome:

No embryo availability rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

异位妊娠率

指标类型:

次要指标

Outcome:

Ectopic pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

因病人分散就诊的特点,为保证每组每种扳机方式人数相等,运用SPSS25.0软件采用随机数字表法将患者进行单纯随机化分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

Due to the characteristics of scattered patients, in order to ensure the equal number of people in each type of trigger in each group, SPSS25.0 software was used to randomize the patients simply by random digital table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

在随访以及用药过程中不采用盲法。

Blinding:

Bding was not used during follow-up as well as during medication.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:从西囡妇科医院的病历系统中收集患者数据; 数据管理:完成的病例报告表由检察员审核后上交,在Epidate双录入数据建立数据库,并进行逻辑查错,在研究结束后保存完整的原始资料并存档。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: collect patient data from the medical record system of Xi'nan Gynecology Hospital; Data management: The completed case report form is reviewed and submitted by the inspector, and the data is double-entered in Epidate to establish a database and perform logical error checking. The complete source material is preserved and archived after the study.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-07-03 13:32:32